AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Clinical Trials Related to Myelodysplastic Syndromes
Related studies linked through entity extraction aliases.
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Monitoring Mutational Burden in Low Risk MDS Patients Using Sequential Peripheral Blood Samples
- Status
- RECRUITING
- Phase
- N/A
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
- Status
- RECRUITING
- Phase
- PHASE1
Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Enhanced Palliative Care in MDS and AML
- Status
- UNKNOWN
- Phase
- NA
SNS-301 Monotherapy in High Risk MDS and CMML
- Status
- WITHDRAWN
- Phase
- PHASE2
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE2
5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
An European Platform for Translational Research in Myelodysplastic Syndromes
- Status
- UNKNOWN
- Phase
- N/A
NTX-301 in MDS/AML
- Status
- COMPLETED
- Phase
- PHASE1
Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
CD123-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
- Status
- COMPLETED
- Phase
- PHASE2
Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)
- Status
- TERMINATED
- Phase
- PHASE3
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
- Status
- ENROLLING_BY_INVITATION
- Phase
- PHASE2
Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results
- Status
- UNKNOWN
- Phase
- N/A
Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
- Status
- COMPLETED
- Phase
- PHASE2
Observational Study Towards the Impact of Newly Started Treatment in MDS on QoL
- Status
- COMPLETED
- Phase
- N/A
A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
- Status
- WITHDRAWN
- Phase
- PHASE2